Systemic Antibacterial Agents

Snodgrass, Alexandra; Motaparthi, Kiran

doi:10.1016/b978-0-323-61211-1.00009-7

Cited by 7 publications

(9 citation statements)

References 383 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Microbial Targeting Strategiesmentioning

confidence: 99%

“…Vancomycin is a broad-spectrum glycopeptide antibiotic that specifically binds Gram-positive bacteria, including staphylococci, streptococci, and most enterococci, through hydrogen bonds between its carbonyl and amine groups and the peptidoglycans found onto the cell wall [ 91 , 92 , 93 ]. The mechanisms of action mainly involve the inhibition of the cell wall synthesis by forming non-covalent complexes with the C-terminal L-Lys-D-Ala-D-Ala motif within the bacterial peptidoglycan precursors and the inhibition of RNA synthesis [ 92 , 93 , 94 ]. While the administration of vancomycin has resulted in the development of vancomycin-resistant Staphylococcus aureus , vancomycin-intermediate Staphylococcus aureus , and vancomycin-resistant enterococci [ 92 ], its attachment onto the surface of nanoparticles has allowed for the capture of both Gram-positive and Gram-negative bacteria within complex samples, such as urine or blood [ 91 ].…”

Section: Microbial Targeting Strategiesmentioning

confidence: 99%

“…The mechanisms of action mainly involve the inhibition of the cell wall synthesis by forming non-covalent complexes with the C-terminal L-Lys-D-Ala-D-Ala motif within the bacterial peptidoglycan precursors and the inhibition of RNA synthesis [92][93][94]. While the administration of vancomycin has resulted in the development of vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate Staphylococcus aureus, and vancomycin-resistant enterococci [92], its attachment onto the surface of nanoparticles has allowed for the capture of both Gram-positive and Gramnegative bacteria within complex samples, such as urine or blood [91].…”

Section: Antimicrobial Drugsmentioning

confidence: 99%

See 2 more Smart Citations

Polymeric Nanoparticles for Antimicrobial Therapies: An up-to-date Overview

et al. 2021

View full text Add to dashboard Cite

Despite the many advancements in the pharmaceutical and medical fields and the development of numerous antimicrobial drugs aimed to suppress and destroy pathogenic microorganisms, infectious diseases still represent a major health threat affecting millions of lives daily. In addition to the limitations of antimicrobial drugs associated with low transportation rate, water solubility, oral bioavailability and stability, inefficient drug targeting, considerable toxicity, and limited patient compliance, the major cause for their inefficiency is the antimicrobial resistance of microorganisms. In this context, the risk of a pre-antibiotic era is a real possibility. For this reason, the research focus has shifted toward the discovery and development of novel and alternative antimicrobial agents that could overcome the challenges associated with conventional drugs. Nanotechnology is a possible alternative, as there is significant evidence of the broad-spectrum antimicrobial activity of nanomaterials and nanoparticles in particular. Moreover, owing to their considerable advantages regarding their efficient cargo dissolving, entrapment, encapsulation, or surface attachment, the possibility of forming antimicrobial groups for specific targeting and destruction, biocompatibility and biodegradability, low toxicity, and synergistic therapy, polymeric nanoparticles have received considerable attention as potential antimicrobial drug delivery agents. In this context, the aim of this paper is to provide an up-to-date overview of the most recent studies investigating polymeric nanoparticles designed for antimicrobial therapies, describing both their targeting strategies and their effects.

show abstract

Section: Microbial Targeting Strategiesmentioning

confidence: 99%

Section: Microbial Targeting Strategiesmentioning

confidence: 99%

Section: Antimicrobial Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Polymeric Nanoparticles for Antimicrobial Therapies: An up-to-date Overview

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It is highly lipophilic, allowing it to reach high drug concentrations in the skin and nail unit. 2 Patients taking minocycline long term and at high doses are at greatest risk for pigment deposition. 3,4 Minocycline-induced hyperpigmentation is classified into 3 types.…”

Section: The Diagnosismentioning

confidence: 99%

Chronic Hyperpigmented Patches on the Legs

Kolodziejczyk

Fronek

Esguerra

2021

Cutis

View full text Add to dashboard Cite

“…Its mechanism of action involves reversibly binding to the 30S ribosomal subunit to prevent bacterial protein synthesis. It is commonly used for short-term therapy in the treatment of acute infections, such as ones caused by methicillin-resistant Staphylococcus aureus, and in the long-term management of acne vulgaris [ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

Doxycycline-Associated Hyperpigmentation: A Case Report and Literature Review

Afrin¹,

Cohen²

2022

Cureus

View full text Add to dashboard Cite

Drug-induced hyperpigmentation is an adverse cutaneous effect; it has been associated with several systemic medications. A healthy 40-year-old man developed facial and dorsal hand hyperpigmentation within two weeks of beginning doxycycline monohydrate 100 milligrams twice daily for acne. Skin pigmentation significantly diminished at a follow-up evaluation two months after discontinuing the medication. Doxycycline-associated skin hyperpigmentation, albeit uncommon, has been described in 18 patients in the literature, including our patient. The demographics included 13 males and five females ranging in age from 11 to 87 years; eight of the patients were less than 50 years old and ten of the patients were over 60 years old. Doxycycline-associated hyperpigmentation frequently occurs on the face and can occur at the site of a previous scar. In most cases, doxycycline was discontinued with the resolution of hyperpigmentation.

show abstract

Systemic Antibacterial Agents

Cited by 7 publications

References 383 publications

Polymeric Nanoparticles for Antimicrobial Therapies: An up-to-date Overview

Polymeric Nanoparticles for Antimicrobial Therapies: An up-to-date Overview

Chronic Hyperpigmented Patches on the Legs

Doxycycline-Associated Hyperpigmentation: A Case Report and Literature Review

Contact Info

Product

Resources

About